^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    peretinoin (K-333)

    i
    Other names: K-333, NIK-333, Ruchiko
    Associations

    News

    Trials
    Company:
    Kowa
    Drug class:
    Apoptosis stimulant, Retinoid X receptor agonist
    Related drugs:
    Associations

    News

    Trials
    over1year
    Acyclic retinoid peretinoin reduces hemorrhage-associated brain injury in vitro and in vivo. (PubMed, Eur J Pharmacol)
    On the other hand, nuclear factor-κB (NF-κB) inhibitors such as pyrrolidine dithiocarbamate (50 μM) and Bay11-7082 (10 μM) prevented thrombin-induced shrinkage of the striatal region...We also found that daily administration of peretinoin reduced histopathological injury and alleviated motor deficits in a mouse model of intracerebral hemorrhage. These results indicate that NR1B agonists including peretinoin may serve as a therapeutic option for hemorrhagic brain injury.
    Preclinical • Journal
    |
    Amnolake (tamibarotene) • Bay11-7082 • peretinoin (K-333)
    over4years
    Dedifferentiation of hepatocellular carcinoma: molecular mechanisms and therapeutic implications. (PubMed, Am J Transl Res)
    Additionally, peretinoin as a potential drug is in progress of several phase III clinical trials. It's promising that differentiation therapy for HCC may be a part of options in future HCC treatment.
    Review • Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    peretinoin (K-333)